Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor PD-0325901 for Patients With KRAS Mutant Non-Small Cell Lung Cancer and Other Solid Tumors
Latest Information Update: 21 Mar 2024
At a glance
- Drugs Mirdametinib (Primary) ; Palbociclib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 18 Mar 2024 Phase of this study has been amended to Phase 1 from Phase 1/2.
- 18 Mar 2024 Status changed from active, no longer recruiting to completed.
- 09 Jul 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.